114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
经导管动脉化疗栓塞术联合微波消融治疗复发性 Spiegel 叶肝细胞癌：四例病例系列
Authors Guan X, Hou R , Han Z, Piao X, Zhang S
Received 24 August 2025
Accepted for publication 6 December 2025
Published 19 December 2025 Volume 2025:12 Pages 2839—2844
DOI https://doi.org/10.2147/JHC.S558992
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr David Gerber
Xin Guan,1,* Ruosen Hou,2,* Zhezhu Han,1 Xuezhe Piao,1 Songnan Zhang1
1Department of Oncology, Yanbian University Hospital, Yanji, Jilin, People’s Republic of China; 2Department of Oncology, China Medical University, Shenyang, Liaoning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Songnan Zhang, Department of Oncology, Yanbian University Hospital, Yanji, Jilin, People’s Republic of China, Email zhangsn21@163.com
Background: The Spiegel lobe, a distinct subdivision of the hepatic caudate lobe, is characterized by its unique anatomical position, with close proximity to major hilar vasculature and extrahepatic structures. Therapeutic intervention for Spiegel lobe lesions remains technically challenging, with no established treatment protocol currently available.
Case Presentation: This study reports four cases of recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe treated with conventional transarterial chemoembolization (c-TACE) followed by microwave ablation (MWA) via a transhepatic left lobe approach. Postprocedural imaging assessment confirmed complete response (CR) in all patients according to mRECIST criteria. During a mean follow-up period of 33.75 months (range: 31– 37), three patients maintained disease-free status, whereas one patient developed intrahepatic recurrence at 19.2 months. This patient achieved CR after repeat TACE-MWA combined with adjuvant lenvatinib and tislelizumab therapy. The mean overall survival (OS) was 33.75 months (95% CI: 31.2– 36.3).
Conclusion: The combination of transcatheter arterial chemoembolization (TACE) and microwave ablation (MWA) for treating recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe was proven feasible in this series of studies, and demonstrated favorable efficacy and safety profiles.
Keywords: Spiegel lobe, recurrent hepatocellular carcinoma, microwave ablation, transcatheter arterial chemoembolization
1Department of Oncology, Yanbian University Hospital, Yanji, Jilin, People’s Republic of China; 2Department of Oncology, China Medical University, Shenyang, Liaoning, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Songnan Zhang, Department of Oncology, Yanbian University Hospital, Yanji, Jilin, People’s Republic of China, Email zhangsn21@163.com
Background: The Spiegel lobe, a distinct subdivision of the hepatic caudate lobe, is characterized by its unique anatomical position, with close proximity to major hilar vasculature and extrahepatic structures. Therapeutic intervention for Spiegel lobe lesions remains technically challenging, with no established treatment protocol currently available.
Case Presentation: This study reports four cases of recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe treated with conventional transarterial chemoembolization (c-TACE) followed by microwave ablation (MWA) via a transhepatic left lobe approach. Postprocedural imaging assessment confirmed complete response (CR) in all patients according to mRECIST criteria. During a mean follow-up period of 33.75 months (range: 31– 37), three patients maintained disease-free status, whereas one patient developed intrahepatic recurrence at 19.2 months. This patient achieved CR after repeat TACE-MWA combined with adjuvant lenvatinib and tislelizumab therapy. The mean overall survival (OS) was 33.75 months (95% CI: 31.2– 36.3).
Conclusion: The combination of transcatheter arterial chemoembolization (TACE) and microwave ablation (MWA) for treating recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe was proven feasible in this series of studies, and demonstrated favorable efficacy and safety profiles.
Keywords: Spiegel lobe, recurrent hepatocellular carcinoma, microwave ablation, transcatheter arterial chemoembolization